RECRUITING

Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research

Conditions

Non Small Cell Lung Cancer lung cancer NSCLC

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The study objective is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with active lung cancer to investigate the immune response to develop treatments and therapies.

Official Title

Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research

Quick Facts

Study Start:2022-02-19

Study Completion:2024-03-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05669105

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 100 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Participants willing and able to provide written informed consent * Participants are willing and able to provide appropriate photo identification * Participant's age 18 - 100 years old * Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or Squamous Cell only. All stages are acceptable.) * Participants must have associated tissue biomarker data (EFGR and MET mutations) in their medical records	* Participants who are pregnant or nursing * Participants with a known history of HIV, hepatitis, or other infectious diseases * Participants who have taken an investigational product in the last 30 days * Participants who have experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the previous two months * Participants currently enrolled in a clinical trial * Participants currently in remission

Inclusion Criteria

Exclusion Criteria

* Participants willing and able to provide written informed consent
* Participants are willing and able to provide appropriate photo identification
* Participant's age 18 - 100 years old
* Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or Squamous Cell only. All stages are acceptable.)
* Participants must have associated tissue biomarker data (EFGR and MET mutations) in their medical records

* Participants who are pregnant or nursing
* Participants with a known history of HIV, hepatitis, or other infectious diseases
* Participants who have taken an investigational product in the last 30 days
* Participants who have experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the previous two months
* Participants currently enrolled in a clinical trial
* Participants currently in remission

Contacts and Locations

Study Contact

Thomas Goslin

CONTACT

(818) 583-8844

tgoslin@sanguinebio.com

Study Locations (Sites)

Sanguine Biosciences

Waltham, Massachusetts, 02451

United States

Collaborators and Investigators

Sponsor: Sanguine Biosciences

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-02-19

Study Completion Date2024-03-31

Study Record Updates

Study Start Date2022-02-19

Study Completion Date2024-03-31

Terms related to this study

Keywords Provided by Researchers

lung cancer
NSCLC

Additional Relevant MeSH Terms

Non Small Cell Lung Cancer